Last reviewed · How we verify
Autologous platelets rich plasma
Autologous platelet-rich plasma (PRP) delivers concentrated growth factors and cytokines from the patient's own platelets to promote tissue repair and reduce inflammation.
Autologous platelet-rich plasma (PRP) delivers concentrated growth factors and cytokines from the patient's own platelets to promote tissue repair and reduce inflammation. Used for Osteoarthritis (knee, shoulder, hip), Tendon and ligament injuries, Muscle injuries.
At a glance
| Generic name | Autologous platelets rich plasma |
|---|---|
| Also known as | PRP |
| Sponsor | Mostafa Hassanein, Msc |
| Drug class | Autologous cell therapy / Regenerative medicine product |
| Modality | Biologic |
| Therapeutic area | Orthopedics, Regenerative Medicine, Wound Healing |
| Phase | FDA-approved |
Mechanism of action
PRP is prepared by centrifuging the patient's blood to concentrate platelets, which are then injected into damaged tissues. The platelets release bioactive molecules including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), and other cytokines that stimulate angiogenesis, cell proliferation, and tissue regeneration. This autologous approach minimizes immunogenic rejection while leveraging the patient's own healing mechanisms.
Approved indications
- Osteoarthritis (knee, shoulder, hip)
- Tendon and ligament injuries
- Muscle injuries
- Chronic wounds
- Hair loss (androgenetic alopecia)
Common side effects
- Injection site pain or discomfort
- Temporary swelling or inflammation
- Infection at injection site
- Allergic reaction (rare)
Key clinical trials
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study. (NA)
- Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis (NA)
- Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy (NA)
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous platelets rich plasma CI brief — competitive landscape report
- Autologous platelets rich plasma updates RSS · CI watch RSS
- Mostafa Hassanein, Msc portfolio CI